Ascletis Pharma (OTCMKTS:ASCLF) is a clinical‐stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the research, development and commercialization of therapies for viral and liver diseases. Since its founding in 2013, the company has built an integrated platform spanning small‐molecule discovery, process chemistry and clinical development. Ascletis is listed on the Hong Kong Stock Exchange and maintains facilities for both clinical research and commercial manufacturing in Mainland China.
The company’s core pipeline focuses on direct‐acting antiviral agents targeting hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Lead assets include ASC22, an HCV NS5B polymerase inhibitor, and ASC09, an HIV‐1 protease inhibitor designed for once‐daily oral dosing. Ascletis also develops novel therapies for HBV, including nucleos(t)ide analogues and immune modulators, and has advanced preclinical candidates aimed at nonalcoholic steatohepatitis (NASH) and liver fibrosis.
In addition to its small‐molecule antivirals, Ascletis leverages traditional Chinese medicine (TCM) heritage to create proprietary formulations for liver health. Products such as Fu Zheng Hua Yu capsules combine herbal extracts with scientific validation, addressing patients in China and select Asian markets. The company engages in strategic partnerships and licensing agreements to expand the geographic reach of its marketed and clinical‐stage assets, with a focus on enhancing global access to its therapies.
Led by founder and chairman Xu Wu, Ascletis Pharma’s leadership team comprises seasoned biopharma executives with extensive experience in drug development, regulatory affairs and commercial operations. The company continues to advance its pipeline through multiple Phase 2 and Phase 3 trials, aiming to deliver innovative, safe and effective treatments for chronic viral infections and liver disorders worldwide.
AI Generated. May Contain Errors.
